middle.news
Neurizon Launches Pivotal Phase 2/3 Trial of NUZ-001 in ALS Patients
9:30am on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
Neurizon Launches Pivotal Phase 2/3 Trial of NUZ-001 in ALS Patients
9:30am on Thursday 26th of February, 2026 AEDT
Key Points
First participant dosed in Regimen I of HEALEY ALS Platform Trial
Adaptive Phase 2/3 trial enrolling ~160 ALS patients across US centres
Trial designed to assess NUZ-001 efficacy and safety over 36 weeks
Follows positive Phase 1 results showing safety and preliminary efficacy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEURIZON THERAPEUTICS (ASX:NUZ)
OPEN ARTICLE